WO1994001110A1 - 5'-INDOLINYL OXAZOLIDINONES USEFUL AGAINST $i(MYCOBACTERIUM TUBERCULOSIS) - Google Patents
5'-INDOLINYL OXAZOLIDINONES USEFUL AGAINST $i(MYCOBACTERIUM TUBERCULOSIS) Download PDFInfo
- Publication number
- WO1994001110A1 WO1994001110A1 PCT/US1993/004850 US9304850W WO9401110A1 WO 1994001110 A1 WO1994001110 A1 WO 1994001110A1 US 9304850 W US9304850 W US 9304850W WO 9401110 A1 WO9401110 A1 WO 9401110A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- indolinyl
- oxazolidinone
- mixture
- acetamidomethyl
- tuberculosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Definitions
- the invention is the use of two 5'-indolinyl oxazolidionones (I) to treat tuberculosis
- Tuberculosis (TB) is a well known disease which is caused by M. tuberculosis.
- agents are used to treat those infected with TB.
- the most common of these pharmaceutical agents include isoniazid, rifampin, ethambutol, p-aminosalicylic acid, pyrazinamide, streptomycin, capreomycin, cycloserine, ethionamide and kanamycin and aminoglycosides antibiotics and mixtures thereof.
- US Patent 4,128,654 discloses 5-halomethylphenyl-2-oxazolidinones which are useful in controlling fungal and bacterial diseases of plants.
- US Patent 4,250,318 discloses 3-substituted phenyl-5-hydroxymethyloxazolidinones having anti depressive utility.
- US Reissue Patent 29,607 discloses 3-substituted phenyl-5-hydroxymethyloxazolidinones having antidepressive, tranquilizing and sedative utility.
- US Patent 4,340,606 discloses 3-(p-alkylsulfonyl)phenyl-5-(hydroxymethyl or acyloxymethyl)oxazolidinones having antibacterial activity in mammals.
- Belgium Patent 892,270 discloses 3-(arylalkyl, arylalkenyl or arylacetylenic substituted)phenyl)-5-(aminomethyl)oxazolidinones which are inhibitors of monoamine oxidase.
- US Patent 4,461,773 discloses 3-substituted phenyl-5-hydroxymethyloxazolidinones which have antibacterial activity.
- European Patent Publications 127,902 and 184,170 disclose 3-substituted phenyl-5- amidomethyloxazolidinones which have antibacterial utility.
- Antimicrobial Agents and Chemotherapy 1791 (1987) discusses compounds disclosed in European Patent Publications 127,902 and 184,170, discussed above, and compares these new compounds with known antibiotics.
- US Patent 4,705,799 discloses aminomethyloxooxazolidinyl benzene derivatives including sulfides, sulfoxides, sulfones and sulfonamides which possess antibacterial activity.
- US Patent 4,801,600 discloses 6'-indolinyloxazolidinones (where the indolinyl nitrogen is meta to the oxazolidinone nitrogen).
- DUP-721 is active against tuberculosis.
- Disclosed is a method of treating humans who have tuberculosis caused by Mycobacterium tuberculosis which comprises admisitration of an effective amount of a 5'- indolinyl oxazolidinone selected from the group consisting of
- 5 '-indolinyl oxazolidinones are known, see International Publication No. WO90/02744, the compounds of formula (XI).
- the 5 '-indolinyl oxazolidinones contain an asymmetric center and therefore produce two enantiomers one "S” and the other "R", either of which can be (+/d) and the other (-/l).
- (+)-3-(5'-l-Hydroxyacetylindolinyl)-5 ⁇ -(acetamidomethyl)oxazolidin-2-one is known, see International Publication No. WO90/02744, EXAMPLES 122.
- the antibacterially active form of the compound is the "S" enantiomer and is disclosed in EXAMPLE 150 as obtained by resolution of a racemic mixture.
- the optically active form was termed 3-(5'-l- hydroxyacetylindolinyl)-5B-(acetamidomethyl)oxazolidin-2-one in International Publication No. WO90/02744.
- a preferred name is 5-(S)-N-( -hydroxyacetyl-5'-indolinyl)-5- (acetamidomethyl)-2-oxazoIidinone.
- racemic forms of the oxazolidinones are useful in treating TB, it is highly preferable to use the active enantiomer rather than the racemic form.
- optically active form can be obtained by resolution of a racemic mixture as set forth in International Publication No. WO90/02744, it is preferred to prepare the desired enantiomer by a stereoselective synthesis.
- One method to produce 5-(S)-N-(r-hydroxyacetyl-5'-indolix ⁇ yl)-5-(acetamidomethyl)- 2-oxazolidinone is by resolution of the racemic form. Another method is by the process of EXAMPLES 1-9. The preferred method, as discussed below, is by the process of EXAMPLES 14-19.
- the preferred method of making the optically active is by starting with the known 1- carbo-t-butyloxy-(N :a- ⁇ obenzyloxy)-5-aminoindoline [US Patent 5,164,510, EXAMPLE 11, compound (IV)] in a solution of tetrahydrofuran or ether at -78° under an inert atmosphere, preferrably nitrogen, and treating with n-butyl lithium/hexane, followed by the addition of (R)- glycidyl butyrate and allowing the mixture to warm to 20-25°.
- This method produces in high yield the optically active 5-hydroxymethyl oxazolidinone having the desired stereochemistry (R), i.e., the 5- ⁇ configuration, see EXAMPLE 14.
- EXAMPLE 16 discloses that the 5-phthalimidomethyl compound is then treated with a reagent to remove the phthalimide group such as an aqueous solution of methylamine or hydrazine to give the intermediate 5-aminomethyl oxazolidinone.
- EXAMPLE 17 discloses the removal of the protecting group by the addition of trifluoroacetic acid, either neat, or in methylene chloride, to give the parent indoline oxazolidinone.
- EXAMPLE 18 discloses acylation on the indoline nitrogen is effected by the addition of benzyloxylacetyl chloride in the presence of triethy.ainine or diisopropylethylamine in methylene chloride or ether, to give the benzyloxyacetylindolinyl compound.
- Treatment of this compound with hydrogen in the presence of palladium black or palladium charcoal in ethyl acetate or methanol gives (S)-5-acetamidomethyI 3(5'-l-hydroxyacetylindolinyl)- oxazolidinone.
- EXAMPLE 17 When the product of EXAMPLE 17 is acylated with 2-thiophenecarbonyl chloride (EXAMPLE 20) the product is 5-(S)-N-( 1 '-(2-thiophenecarbonyl)-5 ' -indolinyl)-5- (acet ⁇ midomethyl)-2-oxazolidinone.
- the 5 '-indolinyl oxazolidinones are administered either parenterally or orally. It is known to those skilled in the art how to formulate the 5 '-indolinyl oxazolidinones into appropriate pharmaceutical dosage forms for oral (tablet, capsule) or parenteral (sterile solution) use utilizing an appropriate solvent such as propylene glycol.
- the 5 '-indolinyl oxazolidinones are useful in treating tuberculosis in humans infected with strains of M. tuberculosis which are susceptible to these antibiotics.
- the 5 '-indolinyl oxazolidinones are administered at doses from about 50 to about 3,000 mg/day. It is preferred that the 5 '-indolinyl oxazolidinones are administered at doses of about 100 to about 2,000 mg/day.
- the 5'-indolinyl oxazolidinones are administered orally and the total daily dose is divided between one to four doses per day.
- the 5 '-indolinyl oxazolidinones can either be used alone, or used in combination with each other or with other antibiotics as is known to those skilled in the art.
- Preferred drugs to be used in combination with 5 '-indolinyl oxazolidinones include, but are not limited to, isoniazid, rifampin, ethambutol, p-aminosalicylic acid, pyrazinamide, streptomycin, kanamycin, capreomycin, cycloserine, and ethionamide.
- TLC refers to thin-layer chromatograph.
- THF refers to tetrahydrofuran.
- Saline refers to an aqueous saturated sodium chloride solution.
- the ratios of solvents used are volume/volume (v/v).
- the solubility of a solid in a solvent is used the ratio of the solid to the solvent is weight volume (wt v).
- IR refers to infrared spectroscopy.
- [ ⁇ ] D 25 refers to the angle of rotation of plant polarized light (specific optical rotation) at 25° with the sodium D line (5893A).
- MS refers to mass spectrometry expressed as m/e or mass/charge unit.
- [M + H] + refers to the positive ion of a parent plus a hydrogen atom.
- El refers to electron impact CI refers to chemical ionization.
- FAB refers to fast atom bombardment.
- Pharmaceutically acceptable refers to those properties and/or substances which are acceptable to the patient from a pharmacological ⁇ oxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability.
- M. tuberculosis refers to Mycobacterium tuberculosis.
- Triethylamine 45 ml is added to a solution of 5-nitroindoline (42.05 g) in tetrahydrofuran (250 ml) and the mixture cooled to 0°, then a solution of benzyloxyacetyl chloride (48.6 g) in THF (50 ml) is added over 15 min, and the mixture stirred in the ice bath for an additional 1.25 hr, then allowed to warm to 20-25° over 3 hr. Aqueous workup yields a solid which is recrystallized from acetone/water to give the title compound, mp 137-139°.
- EXAMPLE 2 N-Benzyloxyacetyl-5-amino-indoline (B)
- N-benzyloxyacetyl-5-nitro-indoline (A, EXAMPLE 1, 12.26 g) in methanol/ethyl acetate (18/82, 1.1 1) under nitrogen is added palladium/charcoal (10%, 1.55 g) and the flask alternately evacuated and filled with hydrogen from a balloon (3 times), then the mixture is allowed to stir at 20-25° for 4 hr. The mixture is degassed and then filtered over diatosnaceous earth,, and the pad washed with ethyl acetate. The filtrate is concentrated to a volume of about 200 ml and a crystalline solid is precipitated, which is collected to give the title compound, mp 105-106°. 3 N-Benzyloxyacetyl-5-[(2'-( ⁇ )-hydroxy-3'-butyrate)propylammo]indoline
- EXAMPLE 4 5-(R)-N-(l'-rjer ⁇ zyloxyacetyl-5'-indol yl)-5-G3utyryloxymethyl)-2- oxazolidinone (D) To a mixture of N-benzyloxyacetyl-5-[(2'-(R)-hydroxy-3'-butyrate)propylamino]indoline (C, EXAMPLE 3, 5.8 g) in methylene chloride (255 ml) under nitrogen at -15° is added a solution of phosgene in toluene (1.93 M, 8.4 ml), and the mixture is allowed to slowly warm to 0° over 1 hr.
- d ⁇ sopropylethylamine (5.7 ml) is added in dropwise fashion over 5 min, and the mixture stirred in the ice bath for 50 min, then allowed to warm to 22°, then poured into 1 N hydrochloric acid (50 ml). The layers are separated and the aqueous is extracted with methylene chloride (3 x 25 ml). The combined organic layers are washed successively with (75 ml ea) saturated aqueous sodium bicarbonate, water, and saline, then dried magnesium sulfate, and concentrated under reduced pressure.
- EXAMPLE 6 5-(R)-N-(l '-benzyloxyacetyl-5 '-indolinyl)-5-(hydroxymethyl)-2- oxazolidinone (E) To a solution of 5-( ⁇ )-N-(r-benzyloxyacetyl-5'-indolinyl)-5-(butytyloxymethyl)-2- oxazolidinone (D, EXAMPLE 5, 0.050 g) in methanol (1 ml) is added sodium methoxide in methanol (25%, 2.5 ⁇ l), and the mixture is stirred at 20° for 1 hr, then the mixture is concentrated to give a residue.
- EXAMPLE 7 5-(R)-N-r ⁇ benzyloxyacetyl-5'-indolinyl)-5-(azidomethyl)-2- oxazolidin ie (F) Following the general procedure of US Patent 4,801,600 and making non-critical variations, 5-(R)-N-(l '-benzyloxya( ⁇ tyl-5'-indol yl)-5-(hydroxymethyl)-2-oxazolidinone (E, EXAMPLE 6) is converted to the azide by treatment with methanesulfonyl chloride and triethylamine in methylene chloride, followed by displacement with sodium azide in refluxing acetone-water. This is immediately carried into the following reaction.
- EXAMPLE 8 5-(S)-N-(l '-benzyIoxyacetyl-5 '-indolmyl)-5-(acetamidomethyl)-2- oxazolidinone (H) Following the general procedure of EXAMPLE 2 and making non-critical variations but taking care to monitor the reduction of the azide so that unwanted cleavage of the benzyl group does not take place, 5-( )-N-(r-benzyloxyaceryl-5'-ind ⁇ j ⁇ yl)-5-(azidomethyl)-2-oxazolidinone (F, EXAMPLE 7), is converted into an amine (G) by treatment with palladium/charcoal in 1 arm of hydrogen in ethyl acetate.
- EXAMPLE 8 is dissolved in ethyl acetate and the mixture purged with nitrogen gas, then palladium/charcoal is added followed by hydrogen (balloon) and the mixture is stirred until TLC analysis shows complete conversion of the starting material. The mixture is filtered over diatomaceous earth, concentrated and the residue is purified by column chromatography on silical gel (methanol/ethyl acetate) to give the title compound.
- EXAMPLE 10 N-(t-Butyloxycartjonyl)-5-[(2'-Gi)-hydroxy-3'-butyrate)propylamino]- indoline (J) Following the general procedure of EXAMPLE 3 and making non-critical variations but stitfting with N-(t-butyloxycartx)nyl)-5-aminoindoline, the title compound is obtained.
- EXAMPLE 11 5-(S)-N-(l '-(t-Butyloxyca ⁇ tx)nyl)-5'-indolinyl)-5-(acetamidomethyl)-2- oxazolidinone (K)
- EXAMPLE 13 5-(S)-N-( 1 '-(2-Thiophenecarbonyl)-5 '-indolinyl)-5-(acetamidomethyl)-2- oxazolidinone (P) Following the general procedure of International Publication No. WO90/02744, EXAMPLE 18, and making non-critical variations and starting with 5(S)-N-(5'-indolinyl)-5- (acetamidomethyl)-2-oxazolidinone (L, EXAMPLE 12) and using the appropriate corresponding acylating agent the title compound is obtained.
- EXAMPLE 16 (S)-3-(5 '- 1 -(_ ⁇ t -t-butyloxymdolmyl)-5-(acetamidomethyl)-oxazolidin-2- one (K) A mixture of ( ⁇ )-3-(5'-l-ca ⁇ t ⁇ o-t-butyloxyindolmyl)-5- ⁇ h alimidomethyl)-oxazolidin-2- one (EXAMPLE 15, 8.826 g) in absolute ethanol (100 ml) and aqueous methylamine (40%, 50 ml) is heated to reflux under nitrogen for 1.5 hr. The volatiles are then removed by reduced pressure with heat at 0.1 Torr to give a concentrate.
- Trifluoroacetic acid (5 ml) is added to a mixture of (S)-3-(5'-l-carbo-t- butyloxyindolinyl)-5-(acetamidomethyl)-oxazolidin-2-one (K, EXAMPLE 16, 4.705 g) in methylene chloride (40 ml) at 0° under nitrogen and the ice bath removed. After 4 hour, the mixture is concentrated and methylene chloride (8 ml) and trifluoroacetic acid (7 ml) is added at 20-25°.
- EXAMPLE 18 (S)-3-(5 * -l-Benzyloxyacetylmdoiinyl)-5-(acetamidomethyl)-oxazolidin-2- one Benzyloxyacetyl chloride (2.27 ml) is added dropwise over 5 min to a mixture of (S)-3- (5'-indolinyl)-5-(acetamidomethyl)-oxazolidin-2-one (L, EXAMPLE 17, 3.445 g) and triethylamine (2.62 ml) in methylene chloride (100 ml) at 0° under nitrogen. The mixture is slowly allowed to come to 20° overnight.
- a 58 yr old, 80 kg white male seeks medical attention due to an illness characterized by cough, weakness, night sweats and shortness of breath.
- the patient's chest radiograph shows extensive cavitary disease consistent with a diagnosis of tuberculosis. Sputum cultures are positive for M. tuberculosis, and the organism is found to be resistant to isoniazid, rifampin, and streptomycin.
- the patient is admitted to the hospital and given 5(S)-N-(l'-hydroxyacetyl-5'- indolinyl)-5-(acetamidomethyl)-2-oxazolidinone orally at a total dosage of 2000 mg/day for 4 weeks. Signs and symptoms of tuberculosis slowly disappear, viable M. tuberculosis organisms are no longer isolated from the patients sputum, and the patients chest radiograph returns to normal. The patient is discharged from the hospital.
- a 30 yr old, 60 kg black female is diagnosed with pulmonary tuberculosis.
- Her sputum isolate is determined to be susceptible to both isoniazid and p-aminosalicylic acid. She is treated as an outpatient with a regimen of oral isoniazid and p-aminosalicylic acid, however, returns in 3 weeks because her condition does not improve.
- a new sputum culture grows M. tuberculosis that is resistant to isoniazid.
- the patient is given a 5(S)-N-(r-hydroxyacetyl-5'- indolinyl)-5-(acetamidomethyl)-2-oxazolidinone to take orally at a dose of 1000 mg/day for two months, in addition to the other antibiotics.
- a 36 yr old white male with acquired immune deficiency syndrome presents to his physician with fever, weight loss, and cough.
- the chest radiograph reveals a focal nidus of infection in the lung.
- Expectorated sputum is negative for M. tuberculosis, however, a tissue biopsy taken via bronchoscopy contains culturable M. tuberculosis.
- the patient is placed upon three drug therapy (isoniazid, rifampin, and ethambutol) due to his AIDS condition. The patient initially improves, but then his condition begins to relapse.
- a new sputum culture indicates the presence of M . tuberculosis that has developed resistance to rifampin, but is susceptible to 5(S)-N-(r-hydroxyacetyl-5'-mdolinyl)-5-(acetamidomethyl)-2- oxazolidinone.
- the rifampin portion of the regimen is replaced by 5-(S)-N-(l'-hydroxyacetyl-5'- indolinyl)-5-(acetamidomethyl)-2-oxazolidinone given at an oral dose of 1000 mg day.
- Within 3 weeks the signs and symptoms of tuberculosis are resolved; the patient continues to take the three drug regimen for an additional 8 months.
- a sputum culture taken post-therapy is negative for M. tuberculosis. The patient is then given isoniazid prophylactically for life to prevent recurrence of the infectioa
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93914058A EP0648119A1 (en) | 1992-07-08 | 1993-05-26 | 5'-INDOLINYL OXAZOLIDINONES USEFUL AGAINST $i(MYCOBACTERIUM TUBERCULOSIS) |
KR1019950700069A KR950702417A (en) | 1992-07-08 | 1993-05-26 | 5′-INDOLINYL OXAZOLIDINONES USEFUL AGAINST MYCOBACTERIUM TUBERCULOSIS Useful for Mycobacterium tuberculosis |
AU43865/93A AU666740B2 (en) | 1992-07-08 | 1993-05-26 | 5'-indolinyl oxazolidinones useful against (mycobacterium tuberculosis) |
JP6503294A JPH07508985A (en) | 1992-07-08 | 1993-05-26 | 5'-indolinyloxazolidinones effective against Mycobacterium tuberculosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90938792A | 1992-07-08 | 1992-07-08 | |
US07/909,387 | 1992-07-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994001110A1 true WO1994001110A1 (en) | 1994-01-20 |
Family
ID=25427164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/004850 WO1994001110A1 (en) | 1992-07-08 | 1993-05-26 | 5'-INDOLINYL OXAZOLIDINONES USEFUL AGAINST $i(MYCOBACTERIUM TUBERCULOSIS) |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0648119A1 (en) |
JP (1) | JPH07508985A (en) |
KR (1) | KR950702417A (en) |
AU (1) | AU666740B2 (en) |
CA (1) | CA2136324A1 (en) |
IL (1) | IL106220A0 (en) |
MX (1) | MX9303764A (en) |
TW (1) | TW260608B (en) |
WO (1) | WO1994001110A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981528A (en) * | 1996-02-24 | 1999-11-09 | Zeneca Limited | Antibiotic oxazolidinone derivatives |
US6069145A (en) * | 1996-01-27 | 2000-05-30 | Zeneca Limited | Piperazinonephenyloxazolidinone derivatives and their use as antibacterial agents |
US6110936A (en) * | 1996-05-11 | 2000-08-29 | Zeneca Limited | 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents |
US6194441B1 (en) | 1997-08-22 | 2001-02-27 | Zeneca Ltd. | Oxazolidinone derivatives and their use as antibacterial agents |
US6495551B1 (en) | 1997-11-29 | 2002-12-17 | Michael John Betts | Substituted phenyloxazolidinones and their use as antibiotics |
US6605630B1 (en) | 1997-08-22 | 2003-08-12 | Syngenta Limited | Antibiotic oxazolidinone derivatives |
US6617339B1 (en) | 1998-06-05 | 2003-09-09 | Syngenta Limited | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them |
US6919329B2 (en) | 2002-02-25 | 2005-07-19 | Pharmacia & Upjohn Company | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives |
US7081538B1 (en) | 1999-12-03 | 2006-07-25 | Astrazeneca Ab | Substituted isoxazolines and their use as antibacterial agents |
US7094900B2 (en) | 2002-08-12 | 2006-08-22 | Pharmacia & Upjohn Company Llc | N-Aryl-2-oxazolidinones and their derivatives |
US7141570B2 (en) | 2002-11-21 | 2006-11-28 | Pharmacia & Upjohn Company | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives |
US7141588B2 (en) | 2002-02-25 | 2006-11-28 | Pfizer, Inc. | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives |
US7141583B2 (en) | 2000-04-25 | 2006-11-28 | Astrazeneca Ab | Oxazolidinone derivatives with antibiotic activity |
US7304050B2 (en) | 2003-09-16 | 2007-12-04 | Pfizer Inc. | Antibacterial agents |
US11555033B2 (en) | 2020-06-18 | 2023-01-17 | Akagera Medicines, Inc. | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990002744A1 (en) * | 1988-09-15 | 1990-03-22 | The Upjohn Company | In position 3 substituted-5-beta-amidomethyl-oxazolidin-2-ones |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5314792A (en) * | 1976-07-24 | 1978-02-09 | Rubuobuna Buratsurabusukay Ara | Copolymers of nnvinylmethylpyrazol and diivinyl crossslinking agent and process for producing same |
JPS54110186A (en) * | 1978-02-17 | 1979-08-29 | Tokyo Yuuki Kagaku Kougiyou Kk | Method of mamufacturing weak basic anion exchange resin |
DE3324835A1 (en) * | 1983-07-09 | 1985-01-17 | Cassella Ag, 6000 Frankfurt | CROSSLINKED COPOLYMER, PROCESS FOR PRODUCING IT AND ITS USE AS SORPENT |
JPS6023854A (en) * | 1983-07-19 | 1985-02-06 | Konishiroku Photo Ind Co Ltd | Photographic element |
DE3434137A1 (en) * | 1984-09-18 | 1986-03-20 | Basf Ag, 6700 Ludwigshafen | METHOD FOR THE PRODUCTION OF INSOLUBLE, LITTLE SWELLABLE POWDER-SHAPED POLYMERS |
JPS63130605A (en) * | 1986-11-20 | 1988-06-02 | Tokuyama Soda Co Ltd | Production of anion exchanger |
US4889632A (en) * | 1987-12-10 | 1989-12-26 | Ceskoslovenska Akademie Ved | Macroporous polymeric membranes for the separation of polymers and a method of their application |
GB8829835D0 (en) * | 1988-12-21 | 1989-02-15 | Smith Kline French Lab | Compounds |
JPH03708A (en) * | 1989-05-29 | 1991-01-07 | Koei Chem Co Ltd | Water-absorptive material |
-
1993
- 1993-05-26 KR KR1019950700069A patent/KR950702417A/en not_active Application Discontinuation
- 1993-05-26 AU AU43865/93A patent/AU666740B2/en not_active Expired - Fee Related
- 1993-05-26 EP EP93914058A patent/EP0648119A1/en not_active Withdrawn
- 1993-05-26 JP JP6503294A patent/JPH07508985A/en not_active Withdrawn
- 1993-05-26 WO PCT/US1993/004850 patent/WO1994001110A1/en not_active Application Discontinuation
- 1993-05-26 CA CA002136324A patent/CA2136324A1/en not_active Abandoned
- 1993-06-08 TW TW082104539A patent/TW260608B/zh active
- 1993-06-23 MX MX9303764A patent/MX9303764A/en unknown
- 1993-07-02 IL IL106220A patent/IL106220A0/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990002744A1 (en) * | 1988-09-15 | 1990-03-22 | The Upjohn Company | In position 3 substituted-5-beta-amidomethyl-oxazolidin-2-ones |
Non-Patent Citations (2)
Title |
---|
DIAGN. MICROBIOL. INFECT. DIS. vol. 14, no. 6, 1991, pages 465 - 471 D.R. ASHTEKAR 'Oxazolidinones, a new class of synthetic antituberculosis agents.' cited in the application * |
GOODMAN GILMAN, A. ET AL. (EDS.), 'GOODMAN AND GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS', 7TH EDITION, 1985, MACMILLAN PUBLISHING COMPANY, NEW YORK. * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6069145A (en) * | 1996-01-27 | 2000-05-30 | Zeneca Limited | Piperazinonephenyloxazolidinone derivatives and their use as antibacterial agents |
US5981528A (en) * | 1996-02-24 | 1999-11-09 | Zeneca Limited | Antibiotic oxazolidinone derivatives |
US6638955B2 (en) | 1996-02-24 | 2003-10-28 | Syngenta Limited | Antibiotic oxazolidinone derivatives |
US6365751B1 (en) | 1996-02-24 | 2002-04-02 | Zeneca Ltd. | Antibiotic oxazolidinone derivatives |
US6271383B1 (en) | 1996-02-24 | 2001-08-07 | Zeneca Limited | Antibiotic oxazolidinone derivatives |
US6350775B1 (en) | 1996-05-11 | 2002-02-26 | Zeneca Limited | 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents |
US6110936A (en) * | 1996-05-11 | 2000-08-29 | Zeneca Limited | 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents |
US6194441B1 (en) | 1997-08-22 | 2001-02-27 | Zeneca Ltd. | Oxazolidinone derivatives and their use as antibacterial agents |
US6605630B1 (en) | 1997-08-22 | 2003-08-12 | Syngenta Limited | Antibiotic oxazolidinone derivatives |
US6495551B1 (en) | 1997-11-29 | 2002-12-17 | Michael John Betts | Substituted phenyloxazolidinones and their use as antibiotics |
US6617339B1 (en) | 1998-06-05 | 2003-09-09 | Syngenta Limited | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them |
US7081538B1 (en) | 1999-12-03 | 2006-07-25 | Astrazeneca Ab | Substituted isoxazolines and their use as antibacterial agents |
US7141583B2 (en) | 2000-04-25 | 2006-11-28 | Astrazeneca Ab | Oxazolidinone derivatives with antibiotic activity |
US6919329B2 (en) | 2002-02-25 | 2005-07-19 | Pharmacia & Upjohn Company | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives |
US7141588B2 (en) | 2002-02-25 | 2006-11-28 | Pfizer, Inc. | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives |
US7645781B2 (en) | 2002-02-25 | 2010-01-12 | Pfizer Inc | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives |
US7094900B2 (en) | 2002-08-12 | 2006-08-22 | Pharmacia & Upjohn Company Llc | N-Aryl-2-oxazolidinones and their derivatives |
US7141570B2 (en) | 2002-11-21 | 2006-11-28 | Pharmacia & Upjohn Company | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives |
US7304050B2 (en) | 2003-09-16 | 2007-12-04 | Pfizer Inc. | Antibacterial agents |
US11555033B2 (en) | 2020-06-18 | 2023-01-17 | Akagera Medicines, Inc. | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof |
US11566023B2 (en) | 2020-06-18 | 2023-01-31 | Akagera Medicines, Inc. | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2136324A1 (en) | 1994-01-20 |
EP0648119A1 (en) | 1995-04-19 |
AU666740B2 (en) | 1996-02-22 |
IL106220A0 (en) | 1993-11-15 |
AU4386593A (en) | 1994-01-31 |
KR950702417A (en) | 1995-07-29 |
TW260608B (en) | 1995-10-21 |
MX9303764A (en) | 1994-01-31 |
JPH07508985A (en) | 1995-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3188418B2 (en) | 3- (Fused ring-substituted) phenyl-5β-amidomethyloxazolidin-2-ones and 3- (nitrogen atom-substituted) phenyl-5β-amidomethyloxazolidine-2-ones | |
JP6764970B2 (en) | Tricyclic benzoxabolol compounds and their use | |
EP0648119A1 (en) | 5'-INDOLINYL OXAZOLIDINONES USEFUL AGAINST $i(MYCOBACTERIUM TUBERCULOSIS) | |
US7968564B2 (en) | HIV integrase inhibitors | |
US5182403A (en) | Substituted 3(5'indazolyl) oxazolidin-2-ones | |
JP4773975B2 (en) | Substituted quinolines and their use as mycobacterial inhibitors | |
KR20220154174A (en) | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | |
JPS61134379A (en) | Aminomethyloxooxazolydinylbenzene derivative | |
JP2004525876A (en) | Novel heterocyclic compounds having antibacterial activity, methods for their preparation, and pharmaceutical compositions containing them | |
RU2215740C2 (en) | Oxazolidinone derivatives and pharmaceutical compositions based on thereof | |
JP2009521464A (en) | Nitroimidazole compounds | |
US11332477B2 (en) | Nitrogen containing heterocycle substituted benzoxazine oxazolidinone compound and preparation method and use thereof | |
KR20170117156A (en) | Benzoxaborol compounds and uses thereof | |
US9242973B2 (en) | Chromane compounds | |
NO325656B1 (en) | Anti-acid fast bacterial agents containing pyridone carboxylic acids as the active ingredient | |
CN106317072B (en) | Heterocyclic compounds for the treatment of mycobacterial infections and uses thereof | |
CN104364240B (en) | Drug for preventing or treating mycobacterial diseases | |
US8518928B2 (en) | Therapeutic compounds | |
JP4310191B2 (en) | Taxane derivative crystal and method for producing the same | |
TWI570119B (en) | Crystalline (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyethyl]-4-(4-methoxy-3-[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl)-3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol and uses thereof | |
CN113214288A (en) | Benzo [1,3] oxazine-oxazolidinone compound and preparation method and application thereof | |
FR2605006A1 (en) | 5-FLUOROURACIL DERIVATIVES, PROCESS FOR THEIR PREPARATION, ANTICANCER COMPOSITION CONTAINING THEM AND THEIR USE FOR THE PREPARATION OF A COMPOSITION FOR THE TREATMENT OF CANCER | |
JPH0363275A (en) | 6,11-dihydro-5h-pyrido(2,13-b)(1,4)benzodiazepine- 6-one and -thion and method of using compound thereof for aids prevention and treatment | |
JPH04198185A (en) | Isothiazolo(5,4-b)pyridine derivative | |
JPS61194071A (en) | Pyridine derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2136324 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993914058 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1993914058 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993914058 Country of ref document: EP |